How to access Elevidys from India — the named-patient coordination pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian boy (or, increasingly per expanded labelling, young man) with a genetically confirmed diagnosis of Duchenne muscular dystrophy (DMD) — typically meeting age and functional criteria per current FDA labelling — may be evaluated by their treating paediatric neurologist for Elevidys (delandistrogene moxeparvovec-rokl). Elevidys is FDA-approved, developed by Sarepta Therapeutics, and is a one-time intravenous AAVrh74-based gene therapy delivering a shortened micro-dystrophin transgene. Because Elevidys is a single-dose therapy with serology and mutation gating, access involves a coordinated pathway rather than a routine prescription.

This guide explains the legal and operational pathway, what your paediatric neurologist needs to coordinate, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Elevidys is a one-time intravenous infusion of a recombinant AAVrh74 vector carrying a micro-dystrophin transgene designed to restore production of a shortened, partially functional dystrophin protein. Key eligibility elements:

• Genetically confirmed DMD — with specified deletion/duplication boundaries per current labelling; mutations in exons 8 and 9 are contraindicated per current label.
• Age and functional status — current FDA labelling has expanded progressively; check specific age and ambulation criteria against the current label.
• Anti-AAVrh74 serology — elevated antibody titres exclude eligibility.
• Hepatic and cardiac baseline — required; peri-infusion corticosteroid tapers mitigate hepatic and immune-mediated adverse events.

Administration is at a gene-therapy-qualified paediatric neurology centre. India's paediatric neurology infrastructure is developing its AAV gene-therapy capability at several tertiary centres; depending on the administering-centre option your neurologist selects, the infusion may be delivered in India or via cross-border referral.

Is Elevidys legally accessible for Indian patients?

Yes — via the Central Drugs Standard Control Organisation (CDSCO) named-patient / personal-use import framework and coordination with a gene-therapy-qualified paediatric centre. The mechanism permits a treating physician to import a medicine not yet locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.

Where the administering centre is outside India, the CDSCO and Ministry of Health medical-referral frameworks support cross-border care coordination with documentation covering medical necessity, administering-centre identification, and the return-to-home follow-up plan.

How the pathway works, step by step

1. Consultation with your paediatric neurologist. Genetic DMD confirmation, exon-boundary mutation documentation (with contraindication check), age/functional status, anti-AAVrh74 serology, hepatic and cardiac baseline, clinical rationale letter.
2. Administering-centre identification. A gene-therapy-qualified paediatric neurology centre is nominated — in India where infrastructure is in place, or via cross-border referral otherwise.
3. CDSCO named-patient application. Your physician files the dossier including rationale, patient reference, centre capability attestation, and single-dose plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner and, where applicable, with the manufacturer's global access programme, under DSCSA chain-of-custody.
5. Cold-chain shipment. Elevidys ships with validated ultra-cold-chain logistics to the administering hospital pharmacy timed to the scheduled infusion date.
6. Infusion and monitoring. The centre administers the one-time IV infusion with peri-infusion corticosteroids, hepatic and cardiac monitoring, and structured follow-up per FDA labelling.

What documentation your physician needs

• Clinical rationale letter confirming DMD diagnosis, mutation details (with contraindication check), age/functional status, anti-AAVrh74 serology, hepatic and cardiac baseline, and Elevidys as the indicated treatment
• Verification of NMC / MCI registration
• DMD genetic-testing report
• Anti-AAVrh74 antibody titre
• Baseline hepatic panel and cardiac assessment (ECG / echo)
• Identification of the gene-therapy-qualified administering centre
• Peri-infusion corticosteroid and monitoring plan

Reserve Meds provides a coordination kit that bundles the CDSCO and administering-centre templates reviewers expect to see for paediatric gene-therapy named-patient files.

Costs and timing

Elevidys's US list price for the one-time product sits in an indicative 2026 range of roughly USD 3.2 million. Total cost of care — including the administering centre's infusion, monitoring, and supportive care — adds incremental local-facility cost. International logistics (ultra-cold chain), CDSCO documentation handling, importer-of-record fees, and concierge coordination add further cost. Reserve Meds issues a transparent quote at the start of intake, reflecting that Elevidys is a one-time therapy rather than a recurring-dose product. These figures are indicative, not guaranteed.

Indicative timing — not guaranteed — from intake to infusion is typically 8–16 weeks, driven by serology, centre scheduling, and cold-chain logistics alignment.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: the Indian DMD patient registry has grown through patient-family organisations over the last decade and families routinely coordinate care through DMD foundations. Our documentation flow is designed to work alongside those community networks and to support cross-border referral where an Indian centre is not yet in a position to administer AAV gene therapy.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner and manufacturer access-programme coordination under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and CDSCO review, keyed to the paediatric gene-therapy rationale.
• Logistics. Validated ultra-cold-chain shipment timed to the infusion schedule, plus family travel coordination for cross-border patterns.
• Concierge case lead. A named point of contact for the family through pre-infusion workup, the infusion day, and structured follow-up.

What we do not do: we are not the prescriber, we do not practise medicine, we do not manufacture the gene-therapy product, and we are not the administering centre. All clinical decisions remain with your paediatric neurologist and the gene-therapy centre. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

My son's mutation is in exon 8 or 9 — is he a candidate? Mutations in these exons carry specific contraindications per current labelling. Your neurologist will check against the current label.

Can the infusion happen in India? Where a tertiary centre has the gene-therapy infrastructure and a path through the manufacturer's qualification process, yes. Otherwise, cross-border referral is the alternative — typically to a US or European centre.

Has my son had exon-skipping therapy — does that disqualify him? Prior eteplirsen, golodirsen, casimersen, or viltolarsen is not a contraindication. Your neurologist decides sequencing.

What about corticosteroid use? DMD patients are routinely on daily corticosteroids; Elevidys peri-infusion corticosteroid protocols integrate with baseline regimens. Your team will manage.

Will insurance or philanthropy cover this? Cash-pay is the default for named-patient imports. Some Indian private insurers and DMD philanthropic programmes consider case-by-case support; we supply documentation but do not manage funding directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026 for gene-therapy coordination. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Elevidys coordination.

Add me to the Elevidys waitlist

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.